Hengrui Pharmaceutical's net profit fell by more than 20%in the first half of the year?What happened to the medicine giant Hengrui Medicine?

In the Chinese market, if you want to ask the best industry in recent years, the pharmaceutical industry is definitely a well -deserved first. In the post -epidemic era, everyone gradually began to recognize the importance of medicine. Times, but recently, the semi -annual report of pharmaceutical giant Hengrui Pharmaceutical has been exposed to the news that net profit decreases by more than 20%. What happened to Hengrui Pharmaceutical?

1. Hengrui Pharmaceutical's net profit fell by more than 20%in the first half of the year?

According to surging news, "Medicine Brother" Hengrui Medicine handed over the transcript in the first half of 2022.

On August 19, Jiangsu Hengrui Pharmaceutical Co., Ltd. announced the semi -annual performance of 2022. In the first half of the year, the operating income achieved operating income of 1.0228 billion yuan, the net profit attributable to the mother was 2.119 billion yuan, and the non -net profit of the mother deducted non -net profit was 2.09 billion yuan, a year -on -year decrease of 23.08%, 20.55%, and 24.12%.

The first quarterly report showed that Hengrui Pharmaceutical's revenue was 5.479 billion yuan, a year -on -year decrease of 20.93%; net profit of home mother was 1.237 billion yuan, a year -on -year decrease of 17.35%. In this regard, Hengrui Pharmaceutical's revenue in the second quarter was 4.749 billion yuan and net profit was 882 million yuan, a decrease of 13.32%and 28.7%, respectively.

Hengrui Pharmaceutical was listed on the Shanghai Stock Exchange in 2000. Compared with the data of more than 20 years, Hengrui Pharmaceutical's semi -annual performance has not increased much. The revenue of this semi -annual report has a year -on -year growth rate of Hengrui Pharmaceutical's lowest value, and the net profit of returning mother is second to the year -on -year. 24.56%in the first half of 2003.

The latest semi -annual report shows that Hengrui Pharmaceuticals further streamlined sales staff, continued to reduce sales operation costs, improve sales and operation efficiency, and reduced sales staff more than 2,300 people during the reporting period. While the sales staff declined, the sales costs were also declining. In the first half of the year, sales costs were 3.267 billion yuan, a year -on -year decrease of 29.98%.

2. What happened to the medicine giant Hengrui Medicine?

Seeing the famous pharmaceutical giant Hengrui Pharmaceutical, there is a relatively large -scale performance decline at this time. Many people are asking what is going on with Hengrui Medicine, and how should we look at the current performance of Hengrui Medicine?

First of all, the reason why Hengrui Pharmaceutical became popular because Hengrui Pharmaceutical itself covered a variety of well -known drugs in the process of business development, including early generic drugs, so that the development of then innovative drugs to help Hengrui Medicine has the development A better market performance, which is why Hengrui Pharmaceutical has always had good market progress in the market in recent years. In the process of market development, there is a better room for development of the market. Therefore, I do n’t have full reasons to believe that Hengrui Pharmaceuticals has a lot of product lines in the current development process of the market, which helps it to have a full market for the market in the product market. Maintain the reasons for better development.

Secondly, we carefully analyze why Hengrui Medicine does not perform well. In fact, the core reason is several aspects:

First, the current collection of drug collection and mining of the country has been carried out for a long time, and the price of drugs has been successfully reduced to a relatively low level. A large number of products of Hengrui Pharmaceutical have actually entered a state of volume procurement. That is, the overall income level of Hengrui Pharmaceutical has declined.

Second, the market development of Hengrui Pharmaceutical itself rely on many offline scenes, which is the hospital scene that we are familiar with. It needs to be sold by the hospital. However, in the first half of this year Under the influence of the epidemic, the hospital's own performance has been under great pressure, and naturally, the performance of Hengrui Medicine is not ideal.

The third is that Hengrui's market development is very dependent on the raw material producers of the upstream, but due to the rise in the overall supply chain price, especially the influence of inflation in the world, Hengrui Pharmaceutical's market performance is also in a relative. Insufficient state.

The final result we saw the overall performance of Hengrui Pharmaceutical's performance showing a decline.

Third, we don't have to worry about these problems in the current development of Hengrui Pharmaceutical's own business. Although the volume procurement will reduce the company's income and profits in the short term, after entering a large number of purchases, the sales of many companies themselves no longer worry about sales, and the channels themselves are very mature, and naturally they can control their own costs. In fact, both of them will gradually recover over time, so as long as Hengrui Pharmaceuticals can continue to make a difference in their own innovation fields, the current pressure and problems are only temporary. Existence, so we still have to have full confidence to look at the development of Hengrui Pharmaceutical.

- END -